Bull case
Surrozen is supported by a compelling scientific rationale, as its lead asset SZN-8141 combines Wnt activation with VEGF inhibition to target both vascular repair and leakage in retinal disease, potentially improving efficacy and durability versus single-agent anti-VEGF therapy. Positive read-through from Merck’s BRUNELLO trial in DME strengthens the case for Wnt biology, while Surrozen’s preclinical data showed accelerated vascular regeneration and reduced avascular and neovascular tuft areas in OIR and sCNV models, with observed superiority versus single agents and anti-VEGF. The company also has near-term catalysts, including IND submission anticipated by the end of 3Q26, Phase 1b/2a initiation by year-end 2026, and a PTAB decision reinforcing its patent position, all while management raised modeled DME development probability to 20% and targets greater wet AMD penetration.